Lek Pharmaceuticals D.d.

Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.d.

Darko Kocjan

Rok Grahek

Andrej Bastarda

Matjaz Kracun

Andrej Kocijan

Tomaz Mesar

Tomaz Solmajer

Anton Copar

Breda Rode

Borut Anzic

Damjana Rozman

Tadeja Kuzman

Klementina Fon Tacer

The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.

Oxidative degradation products of atrovastatin calcium

Oxidative degradation products of atorvastatin calcium

The novel derivatives of pyridilethanol (phenylethyl) amines of formula I are described wherein n is an integer from 1 to 4, Ris a hydrogen atom, hydroxyl group or lower Calkoxy group Ris a hydrogen atom or a straight or branched lower Calkyl group X, is hydrogen, fluorine, chlorine, bromine, hydroxyl group, trifluoromethyl group, 3,4-di-Cl,2,4-di-Cl or lower Calkoxy group, the enantiomers, diastereoisomers or racemates thereof or the physiologically acceptable acid addition salts thereof which are ligands of sigma receptors for inhibiting cholesterol biosynthesis and are thus appropriate for the treatment of hypercholesterolemia and hyperlipemia in humans. The greatest lowering of cholesterol was observed by 1-(d-pyridyl)-2-(N-(2-(3,4-dicholorophenyl)ethyl-N-propylamino)ethanol in the form of dihydrobromide salt (signature BK-35, 2HBr).

Derivatives of pyridilethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, process for their preparation and pharmaceutical compositions containing them

Ethylidene derivatives of tricyclic carbapenems

Growing community of inventors

Ljubljana, Slovenia

Darko Kocjan